TRENTON, N.J. (AP) — A less-expensive version of the world's top-selling insulin, Sanofi's Lantus, could go on sale in the U.S. late next year. The French drugmaker Monday settled a lawsuit over patents for Lantus SoloStar, its insulin in a pen-like dispenser.Read more on NewsOK.com